We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Entelos Regs | LSE:ENTL | London | Ordinary Share | COM SHS USD0.001 (REG S) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.50 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jul 2019 to Jul 2024
Entelos Inc. (ENTL.LN), which makes software that lets pharmaceutical companies run "virtual" drug trials using computers, said Wednesday it signed a research deal with GlaxoSmithKline PLC (GSK.LN).
GlaxoSmithKline wants to use Entelos' Hematopoeisis PhysioLab platform to develop drugs for anemia.
Financial terms weren't disclosed.
Company Web site: www.entelos.com
-By Jason Douglas, Dow Jones Newswires; 44-20-7842-9272; jason.douglas@dowjones.com
Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary. You can use this link on the day this article is published and the following day.
1 Year Entelos Regs Chart |
1 Month Entelos Regs Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
